UniProt P43490
Nicotinamide phosphoribosyltransferase (P43490)
Nicotinamide phosphoribosyltransferase (UniProt P43490), EC 2.4.2.12: 134 experimental structures on GenesisL1, 40 ligands bound, 73 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P43490
- Protein
- Nicotinamide phosphoribosyltransferase
- EC
- 2.4.2.12
- Experimental structures
- 134
- Predicted models
- 0
- Ligands
- 40
- Pockets
- 73 · 9 records with a druggable one
Structures
134 records of P43490 in the MolNFT archive: 134 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2E5B | Crystal structure of Human NMPRTase as free-form | x-ray diffraction | A, B | — | — |
| 2E5B | Crystal structure of human nmprtase as free-form | x-ray diffraction | A, B | — | — |
| 2E5C | Crystal structure of Human NMPRTase complexed with 5'-phosphoribosyl-1'-pyrophosphate | x-ray diffraction | A, B | — | — |
| 2E5C | Crystal structure of human nmprtase complexed with 5'-phosphoribosyl- 1'-pyrophosphate | x-ray diffraction | A, B | — | — |
| 2E5D | Crystal structure of Human NMPRTase complexed with nicotinamide | x-ray diffraction | A, B | — | — |
| 2E5D | Crystal structure of human nmprtase complexed with nicotinamide | x-ray diffraction | A, B | — | — |
| 2GVG | Crystal Structure of human NMPRTase and its complex with NMN | x-ray diffraction | A, B, C, D, E, F | — | — |
| 2GVG | Crystal structure of human nmprtase and its complex with nmn | x-ray diffraction | A, B, C, D, E, F | — | — |
| 2GVJ | Crystal Structure of Human NMPRTase in complex with FK866 | x-ray diffraction | A, B | — | — |
| 2GVJ | Crystal structure of human nmprtase in complex with FK866 | x-ray diffraction | A, B | — | — |
| 3DGR | Crystal structure of human NAMPT complexed with ADP analogue | x-ray diffraction | A, B | — | — |
| 3DGR | Crystal structure of human nampt complexed with ADP analogue | x-ray diffraction | A, B | — | — |
| 3DHD | Crystal structure of human NAMPT complexed with nicotinamide mononucleotide and pyrophosphate | x-ray diffraction | A, B | — | — |
| 3DHD | Crystal structure of human nampt complexed with nicotinamide mononucleotide and pyrophosphate | x-ray diffraction | A, B | — | — |
| 3DHF | Crystal structure of phosphorylated mimic form of human NAMPT complexed with nicotinamide… | x-ray diffraction | A, B | — | — |
| 3DHF | Crystal structure of phosphorylated mimic form of human nampt complexed with nicotinamide… | x-ray diffraction | A, B | — | — |
| 3DKJ | Crystal structure of human NAMPT complexed with benzamide and phosphoribosyl pyrophosphate | x-ray diffraction | A, B | — | — |
| 3DKJ | Crystal structure of human nampt complexed with benzamide and phosphoribosyl pyrophosphate | x-ray diffraction | A, B | — | — |
| 3DKL | Crystal structure of phosphorylated mimic form of human NAMPT complexed with benzamide and… | x-ray diffraction | A, B | — | — |
| 3DKL | Crystal structure of phosphorylated mimic form of human nampt complexed with benzamide and… | x-ray diffraction | A, B | — | — |
| 4JNM | Discovery of Potent and Efficacious Urea-containing Nicotinamide Phosphoribosyltransferase (NAMPT)… | x-ray diffraction | A, B | — | — |
| 4JNM | Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (nampt)… | x-ray diffraction | A, B | — | — |
| 4JR5 | Structure-based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt)… | x-ray diffraction | A, B | — | — |
| 4JR5 | Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (nampt)… | x-ray diffraction | A, B | — | — |
| 4KFN | Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt)… | x-ray diffraction | A, B | — | — |
| 4KFN | Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt)… | x-ray diffraction | A, B | — | — |
| 4KFO | Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt)… | x-ray diffraction | A, B | — | — |
| 4KFO | Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt)… | x-ray diffraction | A, B | — | — |
| 4KFP | Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived Ureas as Potent Inhibitors of Human… | x-ray diffraction | A, B | — | — |
| 4KFP | Identification of 2,3-dihydro-1H-PYRROLO[3,4-C]PYRIDINE-derived ureas as potent inhibitors of human… | x-ray diffraction | A, B | — | — |
| 4L4L | Structural Analysis of a Phosphoribosylated Inhibitor in Complex with Human Nicotinamide… | x-ray diffraction | A, B | — | — |
| 4L4L | Structural analysis of a phosphoribosylated inhibitor in complex with human nicotinamide… | x-ray diffraction | A, B | — | — |
| 4L4M | Structural Analysis of a Phosphoribosylated Inhibitor in Complex with Human Nicotinamide… | x-ray diffraction | A, B | — | — |
| 4L4M | Structural analysis of a phosphoribosylated inhibitor in complex with human nicotinamide… | x-ray diffraction | A, B | — | — |
| 4LTS | Discovery of Potent and Efficacious Cyanoguanidine-containing Nicotinamide… | x-ray diffraction | A, B | — | — |
| 4LTS | Discovery of potent and efficacious cyanoguanidine-containing nicotinamide… | x-ray diffraction | A, B | — | — |
| 4LV9 | Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic… | x-ray diffraction | A, B | — | — |
| 4LV9 | Fragment-based identification of amides derived from trans-2-(pyridin- 3-YL)CYCLOPROPANECARBOXYLIC… | x-ray diffraction | A, B | — | — |
| 4LVA | Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic… | x-ray diffraction | A, B | — | — |
| 4LVA | Fragment-based identification of amides derived from trans-2-(pyridin- 3-YL)CYCLOPROPANECARBOXYLIC… | x-ray diffraction | A, B | — | — |
| 4LVB | Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic… | x-ray diffraction | A, B | — | — |
| 4LVB | Fragment-based identification of amides derived from trans-2-(pyridin- 3-YL)CYCLOPROPANECARBOXYLIC… | x-ray diffraction | A, B | — | — |
| 4LVD | Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic… | x-ray diffraction | B, A | — | — |
| 4LVD | Fragment-based identification of amides derived from trans-2-(pyridin- 3-YL)CYCLOPROPANECARBOXYLIC… | x-ray diffraction | B, A | — | — |
| 4LVF | Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic… | x-ray diffraction | A, B | — | — |
| 4LVF | Fragment-based identification of amides derived from trans-2-(pyridin- 3-YL)CYCLOPROPANECARBOXYLIC… | x-ray diffraction | A, B | — | — |
| 4LVG | Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic… | x-ray diffraction | A, B | — | — |
| 4LVG | Fragment-based identification of amides derived from trans-2-(pyridin- 3-YL)CYCLOPROPANECARBOXYLIC… | x-ray diffraction | A, B | — | — |
| 4LWW | Discovery of Potent and Efficacious Cyanoguanidine-containing Nicotinamide… | x-ray diffraction | A, B | — | — |
| 4LWW | Discovery of potent and efficacious cyanoguanidine-containing nicotinamide… | x-ray diffraction | A, B | — | — |
| 4M6P | Identification of Amides Derived From 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic Acid as Potent… | x-ray diffraction | A, B | — | — |
| 4M6P | Identification of amides derived from 1H-PYRAZOLO[3,4-B]PYRIDINE-5- carboxylic acid as potent… | x-ray diffraction | A, B | — | — |
| 4M6Q | Identification of Amides Derived From 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic Acid as Potent… | x-ray diffraction | A, B | — | — |
| 4M6Q | Identification of amides derived from 1H-PYRAZOLO[3,4-B]PYRIDINE-5- carboxylic acid as potent… | x-ray diffraction | A, B | — | — |
| 4N9B | Fragment-based Design of 3-Aminopyridine-derived Amides as Potent Inhibitors of Human Nicotinamide… | x-ray diffraction | A, B | — | — |
| 4N9B | Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide… | x-ray diffraction | A, B | — | — |
| 4N9C | Fragment-based Design of 3-Aminopyridine-derived Amides as Potent Inhibitors of Human Nicotinamide… | x-ray diffraction | A, B | — | — |
| 4N9C | Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide… | x-ray diffraction | A, B | — | — |
| 4N9D | Fragment-based Design of 3-Aminopyridine-derived Amides as Potent Inhibitors of Human Nicotinamide… | x-ray diffraction | A, B | — | — |
| 4N9D | Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide… | x-ray diffraction | A, B | — | — |
74 records more on the page itself.
Ligands
- PO4 · Phosphate ion · in 23 records
- CL · Chloride ion · in 8 records
- NCA · Nicotinamide · in 4 records
- SO4 · Sulfate ion · in 4 records
- 6TA · ~{tert}-butyl (2~{S})-2-[(1,3-dihydropyrrolo[3,4-c]pyridin-2-ylcarbonylamino)methyl]-6-azaspiro[2.5]octane-6-carboxylate · in 2 records
- 7A0 · [(2~{R},3~{S},4~{R},5~{R})-5-[2-azanyl-5-[[[4-[6-(ethylamino)-5-(2-piperidin-1-ylethylcarbamoyl) pyridin-2-yl]-2-fluoranyl-phenyl]carbamoylamino]methyl]pyridin-1-ium-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl dihydrogen phosphate · in 2 records
- 7TA · N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-2H-pyrrolo[3,4-c]pyridine-2-carboxamide · in 2 records
- 8HV · 5-fluoro-N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-2H-isoindole-2-carboxamide · in 2 records
- 8HY · N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-2H-isoindole-2-carboxamide · in 2 records
- CVJ · (1S,2S)-N-{4-[(1S)-1-(propanoylamino)ethyl]phenyl}-2-(pyridin-3-yl)cyclopropane-1-carboxamide · in 2 records
- DPO · Diphosphate · in 2 records
- HVM · (2E)-N-{4-[1-(3-aminobenzene-1-carbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)prop-2-enamide · in 2 records
- QCT · 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-deoxy-alpha-L-mannopyranoside · in 2 records
- 7A1 · 6-[4-[(6-azanylpyridin-3-yl)methylcarbamoylamino]-3-fluoranyl-phenyl]-2-(ethylamino)-~{N}-(2-piperidin-1-ylethyl)pyridine-3-carboxamide · in 1 record
- 7T7 · N-[4-({[(3S)-oxolan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide · in 1 record
- 7YE · N-[4-[(5R)-6-oxidanylidene-5-quinolin-5-yl-5-(trifluoromethyl)-1,4-dihydropyridazin-3-yl]phenyl]-1, 3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide · in 1 record
- 7YK · N-[4-[(4R)-4-methyl-1-(oxan-4-yl)-6-oxidanylidene-4,5-dihydropyridazin-3-yl]phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide · in 1 record
- 7YT · N-[4-[(4R)-1,4-dimethyl-6-oxidanylidene-4,5-dihydropyridazin-3-yl]phenyl]-5,7-dihydropyrrolo[3,4-b]pyridine-6-carboxamide · in 1 record
- 7YX · N-[4-[(4R)-1-cyclopentyl-4-methyl-6-oxidanylidene-4,5-dihydropyridazin-3-yl]phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide · in 1 record
- 7Z2 · N-[4-[(5R)-1-(4-azanylbutyl)-6-oxidanylidene-5-quinolin-5-yl-4,5-dihydropyridazin-3-yl]phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide · in 1 record
- 96Q · (~{E})-3-(6-azanylpyridin-3-yl)-~{N}-[[5-[4-[4,4-bis(fluoranyl)piperidin-1-yl]carbonylphenyl]-7-(4-fluorophenyl)-1-benzofuran-2-yl]methyl]prop-2-enamide · in 1 record
- A12 · Phosphomethylphosphonic acid adenosyl ester · in 1 record
- AOY · (3E)-3-[(phenylamino)methylidene]oxan-2-one · in 1 record
- AQ1 · 2-[(2-fluorophenyl)amino]-6-propylpyrimidin-4(3H)-one · in 1 record
- BWA · N-{4-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) methyl]phenyl}-N'-[(pyridin-3-yl)methyl]urea · in 1 record
- C5V · (1S,2S)-N-{4-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) methyl]phenyl}-2-(pyridin-3-yl)cyclopropane-1-carboxamide · in 1 record
- CVP · 4-[(piperazin-1-yl)methyl]-N-{[4-({[(pyridin-3-yl) methyl]carbamoyl}amino)phenyl]methyl}benzamide · in 1 record
- I7Q · N-{2-[(4R)-2,2-dimethyl-4-(propan-2-yl)oxan-4-yl]ethyl}-N-[(4-methoxyphenyl)methyl]furan-2-carboxamide · in 1 record
- J7F · 2-(2-~{tert}-butylphenoxy)-~{N}-(4-hydroxyphenyl) ethanamide · in 1 record
- MG · Magnesium ion · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.